Allarity Therapeutics, Inc. Cost of Revenue
Allarity Therapeutics, Inc. (ALLR) reported Cost of Revenue of $679.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2023-08-14
- 2023-06-30: Cost of Revenue 6 month $679.00K.
| Period end | Cost of Revenue 6 month |
|---|---|
| 2023-06-30 | $679.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |